ArticleScientific reports2025
Association between serum uric acid levels and left ventricular hypertrophy based on electrocardiographic findings: a sex-specific analysis across cardiometabolic diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uric acid, vitamin D, and left ventricular hypertrophy: Unveiling cardiovascular risks - a retrospective cross-sectional study.Medicine · 2026Article
- Impact of epicardial adipose tissue volume and hypertension on left ventricular hypertrophy in preclinical heart failure patients with metabolic syndrome.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between serum uric acid (UA) levels and left ventricular hypertrophy (LVH) remains unclear. We aimed to investigate this association using electrocardiographic findings. Health examination data from Kagoshima Kouseiren Hospital included 79,200 participants without cardiovascular diseases. Hypertension was defined as a blood pressure ≥ 140/90 mmHg. A Sokolow-Lyon criterion of ≥ 3.5 mm was used to define LVH. Sex-specific associations between UA and LVH were adjusted for age, body mass index, systolic blood pressure, serum triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, estimated glomerular filtration rate, and lifestyle factors. The mean UA levels were 4.5 ± 1.1 and 6.1 ± 1.4 mg/dL in women and men, respectively (LVH prevalences, 4.0%, and 11.8%, respectively). Individuals without and with hypertension had mean UA levels of 5.2 ± 1.4 and 5.7 ± 1.5 mg/dL, respectively (LVH prevalences, 5.5%, and 14.4%, respectively). UA levels were significantly associated with LVH in women aged 40-49 and 50-59 years and in men aged 50-59 years. Compared with the first UA quartile, the fourth quartile showed a more significant association with LVH in individuals without hypertension. Furthermore, UA was associated with LVH in individuals without obesity, dyslipidemia, reduced kidney function, and diabetes in both sexes. Serum UA levels are associated with LVH in middle-aged women and men without cardiovascular disease risk, suggesting the potential role of UA as an LVH marker. Anwar Ahmed Salim and Shin Kawasoe contributed equally to this work.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.